Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

96.91 -1.25 (-1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
58 59 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
From Gilead Sciences, Inc.
Via Business Wire
Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry
Via Benzinga
7 Healthcare Stocks to invest in for a Healthy Future
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase
Pfizer Inc (NYSE: PFE) is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529.  
Via Benzinga
Exposures COVID-19
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock
The companies are hoping to use antibody drug conjugates in lung cancer patients. 
Via Investor's Business Daily
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
From Gilead Sciences, Inc.
Via Business Wire
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement! 
Via InvestorPlace
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership. 
Via Benzinga
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
From Gilead Sciences, Inc.
Via Business Wire
2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now
These companies aren't getting the respect they deserve. 
Via The Motley Fool
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Gilead Sciences, Inc.
Via Business Wire
5 Reasons Gilead Sciences is a Better Buy Than You Think
Gilead Sciences is a value and high-yielding stock on the brink of a stock rebound that could add double-digits to investors portfolios this year an next. 
Via MarketBeat
Exposures COVID-19
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
Wall Street price targets suggest this stock can rocket more than 400% higher. 
Via The Motley Fool
Biotech Sector: On The Verge Of Triumph Or Turmoil?
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
Via Talk Markets
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Pharma Giants Combine Forces to Fight New M&A Rules
Some of pharma's biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms. 
Via The Motley Fool
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
From Gilead Sciences, Inc.
Via Business Wire
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
From Gilead Sciences, Inc.
Via Business Wire
3 Magnificent Dividend Stocks to Buy in October
These stocks come with great dividends and more. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study
Gilead Sciences Inc (NASDAQ: GILD) said it has  
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.